The Why WAIT program: improving clinical outcomes through weight management in type 2 diabetes

Curr Diab Rep. 2008 Oct;8(5):413-20. doi: 10.1007/s11892-008-0071-5.

Abstract

Targeting body weight, as an alternative model to targeting hemoglobin A(1c), is emerging as a viable and potentially cost-effective approach to diabetes management in clinical practice. Why WAIT (Weight Achievement and Intensive Treatment) is a 12-week multidisciplinary program for weight control and intensive diabetes management specifically designed for application in routine diabetes practice. The program, which is generally covered by insurance, is followed by continuous support aimed at long-term maintenance of weight loss and diabetes control. This model was effective in improving key metabolic abnormalities observed in diabetic patients. Eighty-two percent of participants achieved the target hemoglobin A(1c) of less than 7% on less diabetes medications. The achieved weight reduction after 12 weeks of intervention was maintained for an additional year. Future dissemination of this intervention model in routine clinical practice may require wider endorsement by third-party payers and support of governmental health care agencies to halt the progression of the epidemic of obesity and diabetes in the United States.

MeSH terms

  • Body Weight / physiology*
  • Clinical Trials as Topic*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / physiopathology
  • Diabetes Mellitus, Type 2 / prevention & control*
  • Glycated Hemoglobin A / analysis
  • Health Promotion / methods
  • Humans
  • Life Style
  • Middle Aged
  • Treatment Outcome

Substances

  • Glycated Hemoglobin A